From PCOS to PMOS: What the Name Change Means for Women

A new name for a long-misnamed condition, and what it changes for the millions of women who live with it.

On 12 May 2026, The Lancet published the outcome of an 11-year global consensus that quietly changes how more than 170 million women around the world will hear their diagnosis. Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome - PMOS. The new name was developed by 56 academic, clinical and patient organisations, with input from more than 14,300 patients and health professionals across every world region.

Why “polycystic” was always a misnomer

The original name has been criticised by clinicians and patients for decades, and the consensus authors did not mince words: they described “polycystic ovary syndrome” as inaccurate, said it implied pathological ovarian cysts, obscured the condition’s endocrine and metabolic features, and contributed to delayed diagnosis, fragmented care and stigma.

The “cysts” the name refers to are not cysts in the medical sense at all. They are arrested ovarian follicles - small fluid-filled sacs that contain eggs and that normally develop and release each cycle. In the condition, many of these follicles stall in early development. They are not abnormal growths, they are not dangerous in themselves, and crucially, a significant proportion of women who meet the diagnostic criteria have no detectable polyfollicular pattern on ultrasound at all. A name that hinged on a finding many patients do not have was always going to mislead.

What the new name actually describes

Each word of polyendocrine metabolic ovarian syndrome was chosen to do a job.

• Polyendocrine signals that this is a multi-hormone condition. Insulin, androgens (such as testosterone), luteinising hormone and other neuroendocrine signals are all involved - it is not an isolated ovarian disorder.

•     Metabolic puts insulin resistance, weight gain that resists conventional approaches, type 2 diabetes risk and cardiovascular risk where they belong: at the centre of the picture, not as sidenotes.

•      Ovarian preserves the link to the reproductive features (irregular cycles, ovulatory dysfunction, fertility challenges) without making them the whole story.

The Endocrine Society, one of the co-authoring bodies, described the shift as a move away from treating the condition as a primarily gynaecological problem and toward recognising it as a complex, multi-system condition involving endocrine, metabolic, reproductive, dermatological and psychological health.

Why this matters for women

Names shape care. The authors of the consensus paper were explicit that the misleading old name had real-world costs: it pushed clinical attention toward the ovaries and away from the cardiometabolic risks that drive much of the long-term harm, and it left many women bouncing between specialists or being dismissed altogether.

Four practical changes are expected to follow from the rename.

• Earlier and more accurate diagnosis. When the condition is framed as endocrine rather than purely gynaecological, GPs and other front-line clinicians are more likely to consider it in women presenting with insulin resistance, irregular cycles, acne or hirsutism (excessive body hair generally in areas associated with men such as upper lip), rather than ruling it out because an ultrasound looks normal.

• A clearer route to whole-body care. Polyendocrine metabolic ovarian syndrome explicitly invites screening for type 2 diabetes, lipid abnormalities and cardiovascular risk, alongside reproductive and dermatological care.

• Less stigma. The word “cystic” has carried medical connotations - and a degree of fear - that the underlying biology does not warrant. A more accurate name lowers the unnecessary alarm and the shame some patients describe.

• Validation. For the many women who were told their imaging was “normal” and therefore they could not have PCOS, the new name reflects what the science already showed: the condition is real even when the ovaries look ordinary.

What happens next

The change is not just a relabelling exercise. The consensus authors have set out a staged three-year implementation, during which the new terminology will be monitored, refined to accommodate emerging evidence on subtypes, and integrated into the International Evidence-Based Guideline for the Assessment and Management of the condition - a guideline already used across 195 countries and due for its next major update in 2028. Patient organisations have been asked to lead the public-facing transition, so the older PCOS name is likely to persist informally for some time.

For women already living with a PCOS diagnosis: nothing about your condition has changed, and your existing diagnosis remains valid. What has changed is the language clinicians and researchers will increasingly use - language that, after decades of advocacy, finally matches the biology.

Sources

Teede H, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 12 May 2026.

Endocrine Society press release: Polyendocrine Metabolic Ovarian Syndrome — new name to improve diagnosis and care of a condition affecting 170 million women worldwide (2026).

University of Colorado Anschutz Medical Campus: Global Experts Establish New Name for

PCOS to Reflect Multisystem Disease (2026).

Yang L, et al. Rising Incidence, Health Resource Utilization, and Costs of Polycystic Ovary Syndrome in the United Kingdom. Journal of Clinical Endocrinology & Metabolism, 2024.

Ding T, et al. Diagnosis and management of polycystic ovary syndrome in the UK (2004–2014): a retrospective cohort study. BMJ Open / PMC.

World Health Organization: Polycystic ovary syndrome — fact sheet.

Irish Nutrition and Dietetic Institute (INDI): Polycystic Ovary Syndrome (PCOS) — women’s health information.

Archives of Medical Science: National and regional trends in the prevalence of PCOS since 1990 within Europe — modelled estimates from the Global Burden of Disease Study.